{
  "image_filename": "table_p2_det_1_011.png",
  "image_path": "FlublokPI/extracted/figures/table_p2_det_1_011.png",
  "image_type": "Table",
  "page_number": 2,
  "block_id": "det_1_011",
  "claim_id": "claim_004",
  "claim": "Vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
  "supports_claim": false,
  "explanation": "Table listing percentages of solicited local and systemic adverse events (pain, redness, swelling, headache, fatigue, muscle pain, etc.) reported in adult participants receiving Flublok (recombinant influenza vaccine) versus placebo The table provides safety and reactogenicity data comparing Flublok to placebo and does not present any immunogenicity or antibody response results, so it does not support the claim Note: Analysis limited to safety data; immunogenicity information is not shown in this image",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "Table listing percentages of solicited local and systemic adverse events (pain, redness, swelling, headache, fatigue, muscle pain, etc.) reported in adult participants receiving Flublok (recombinant influenza vaccine) versus placebo",
    "evidence_found": null,
    "reasoning": "The table provides safety and reactogenicity data comparing Flublok to placebo and does not present any immunogenicity or antibody response results, so it does not support the claim",
    "confidence_notes": "Analysis limited to safety data; immunogenicity information is not shown in this image"
  }
}